Skip to Main Content

Sample Publications Involving our Laboratory Assays:

Lu L, Katsaros D, Canuto EM, Biglia N, Risch HA, Yu H. LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis. Gynecol Oncol 2016;141(1):121-7. doi: 10.1016/j.ygyno.2015.12.035

Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST, Risch HA, Mu L, Canuto EM, Gregori G, Benedetto C, Yu H. Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Breast Cancer Res Treat 2012;136(3)875-83. doi: 10.1007/s10549-012-2314-z

Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, Deng Q, Scarampi L, Mitidieri M, Katsaros D, Yu H. Physical activity and breast cancer survival—an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. Breast Cancer Res Treat 2012;133(1):127-35. doi: 10.1007/s10549-011-1716-7

Lu L, Katsaros D, Mayne ST, Risch HA, Benedetto C, Canuto EM, Yu H. Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer. Carcinogenesis 2012;33(11):2119-25. doi: 10.1093/carcin/bgs243

Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res 2011;13(3):R56. doi: 10.1186/bcr2893

Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol 2011;122(2):366-71. doi: 10.1016/j.ygyno.2011.04.033

Risch HA, Yu H, Lu L, Kidd MS. ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. J Natl Cancer Inst 2010;102(7):502-5. doi: 10.1093/jnci/djq007

Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007;67(21):10117-22. doi: 10.1158/0008-5472.CAN-07-2544